Arcus Biosciences is a clinical-stage biopharmaceutical company developing investigational therapies in oncology and inflammatory/autoimmune diseases, with no approved products and no product revenue. The company's pipeline includes multiple candidates in various development stages, anchored by zimberelimab, an anti-PD-1 antibody being evaluated in combination regimens, and domvanalimab, being studied alongside zimberelimab in a Phase 3 trial. Arcus relies on strategic partnerships with larger pharmaceutical companies like Gilead (which owns approximately 25% of the company and has significant governance influence) to fund development, conduct clinical trials, and eventually commercialize approved products, as the company has no internal sales, marketing, or manufacturing capabilities of its own.